EIDOS THERAPEUTICS, INC. Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 21 rows, 21 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2018-06-22: Reporting owner BridgeBio Pharma LLC; Form 4; Security Series B Preferred Stock; Transaction X Exercise of in-the-money or at-the-money derivative security.
- 2018-06-22: Reporting owner BridgeBio Pharma LLC; Form 4; Security Series B Preferred Stock; Transaction C Conversion of derivative security.
- 2018-06-22: Reporting owner BridgeBio Pharma LLC; Form 4; Security Series Seed Preferred Stock; Transaction C Conversion of derivative security.
- 2018-06-22: Reporting owner RA Capital Healthcare Fund LP | RA CAPITAL MANAGEMENT, LLC | Kolchinsky Peter; Form 4; Security Series B Convertible Preferred Stock; Transaction C Conversion of derivative security.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2018-06-22 | BridgeBio Pharma LLC 10% Owner | 4 | Series B Preferred Stock Derivative · Direct | X Exercise of in-the-money or at-the-money derivative security | +332,262 2,909,029 owned after | $0.00 | 2018-06-26 | |
| 2018-06-22 | BridgeBio Pharma LLC 10% Owner | 4 | Series B Preferred Stock Derivative · Direct | C Conversion of derivative security | −2,909,029 0 owned after | $0.00 | 2018-06-26 | |
| 2018-06-22 | BridgeBio Pharma LLC 10% Owner | 4 | Series Seed Preferred Stock Derivative · Direct | C Conversion of derivative security | −12,832,123 0 owned after | $0.00 | 2018-06-26 | |
| 2018-06-22 | RA Capital Healthcare Fund LP | RA CAPITAL MANAGEMENT, LLC | Kolchinsky Peter 10% Owner | Director | 10% Owner | 4 | Series B Convertible Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −922,950 0 owned after | $0.00 | 2018-06-22 | |
| 2018-06-22 | Shah Rajeev M. Director | 4 | Series B Convertible Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −922,950 0 owned after | $0.00 | 2018-06-22 | |
| 2018-06-22 | Kumar Neil Director, Officer (Chief Executive Officer), 10% Owner | 4 | Series B Convertible Preferred Stock Derivative · Indirect · See footnote | X Exercise of in-the-money or at-the-money derivative security | +332,262 2,909,029 owned after | $0.00 | 2018-06-22 | |
| 2018-06-22 | Kumar Neil Director, Officer (Chief Executive Officer), 10% Owner | 4 | Series B Convertible Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −2,909,029 0 owned after | $0.00 | 2018-06-22 | |
| 2018-06-22 | Kumar Neil Director, Officer (Chief Executive Officer), 10% Owner | 4 | Series Seed Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −12,832,123 0 owned after | $0.00 | 2018-06-22 | |
| 2018-06-22 | Satvat Ali J. Director, 10% Owner | 4 | Series B Convertible Preferred Stock Derivative · Indirect · See footnote | X Exercise of in-the-money or at-the-money derivative security | +332,262 2,909,029 owned after | $0.00 | 2018-06-22 | |
| 2018-06-22 | Satvat Ali J. Director, 10% Owner | 4 | Series B Convertible Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −2,909,029 0 owned after | $0.00 | 2018-06-22 | |
| 2018-06-22 | Satvat Ali J. Director, 10% Owner | 4 | Series Seed Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −12,832,123 0 owned after | $0.00 | 2018-06-22 | |
| 2018-06-19 holding as of filing | Satvat Ali J. Director, 10% Owner | 3 | Series Seed Convertible Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2018-06-19 | ||
| 2018-06-19 holding as of filing | Satvat Ali J. Director, 10% Owner | 3 | Series B Convertible Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2018-06-19 | ||
| 2018-06-19 holding as of filing | Satvat Ali J. Director, 10% Owner | 3 | Convertible Preferred Warrant (right to buy) Derivative · Indirect · See footnote | Holding | $10.83 exercise price | 2018-06-19 | ||
| 2018-06-19 holding as of filing | Kumar Neil Director, Officer (Chief Executive Officer), 10% Owner | 3 | Series Seed Convertible Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2018-06-19 | ||
| 2018-06-19 holding as of filing | Kumar Neil Director, Officer (Chief Executive Officer), 10% Owner | 3 | Series B Convertible Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2018-06-19 | ||
| 2018-06-19 holding as of filing | Kumar Neil Director, Officer (Chief Executive Officer), 10% Owner | 3 | Convertible Preferred Warrant (right to buy) Derivative · Indirect · See footnote | Holding | $10.83 exercise price | 2018-06-19 | ||
| 2018-06-19 holding as of filing | Shah Rajeev M. Director | 3 | Series B Convertible Preferred Stock Derivative · Indirect · See footnotes | Holding | no price filed | 2018-06-19 | ||
| 2018-06-19 holding as of filing | BridgeBio Pharma LLC 10% Owner | 3 | Series Seed Preferred Stock Derivative · Direct | Holding | no price filed | 2018-06-19 | ||
| 2018-06-19 holding as of filing | BridgeBio Pharma LLC 10% Owner | 3 | Series B Preferred Stock Derivative · Direct | Holding | no price filed | 2018-06-19 | ||
| 2018-06-19 holding as of filing | RA Capital Healthcare Fund LP | RA CAPITAL MANAGEMENT, LLC | Kolchinsky Peter Director | Director | Director | 3 | Series B Convertible Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2018-06-19 |